Abstract

This study aimed to investigate minocycline adjuvant therapy on type 2 diabetic periodontitis and its impact on blood glucose levels. We collected 100 patients with type 2 diabetic periodontitis admitted to our hospital from February 2022 to February 2023 as the study subjects, and then divided them into a control group (50 cases, conventional treatment) and an observation group (50 cases, conventional combined with minocycline treatment) by random number table method, observed and compared the changes in blood glucose, periodontal status and inflammatory indexes in both groups. After treatment, observation group had lower fasting blood glucose, 2 h fasting blood glucose and glycated hemoglobin levels than control group (p<0.05); observation group had lower gingival index, sulcus bleeding index, probing depth, plaque index and clinical attachment loss scores than control group (p<0.05); the levels of interleukin-6, tumor necrosis factor-alpha and C-reactive protein in the observation group were significantly smaller compared with those in the control group (p<0.05). Minocycline adjuvant therapy in the clinical treatment of patients with type 2 diabetic periodontitis can significantly improve the patients' blood glucose, it also improves the patients' periodontal condition and can effectively relieve the patients' inflammatory response, which can effectively improve the prognosis and obtain better treatment effectiveness.